ZyVersa Q1 2023 net loss $3.5M; cash only $1.3M, needs financing

ZyVersa Therapeutics, Inc.

2024-Q1 EPS reported -$135.88 vs consensus -$3.77 ▼ miss (-3500.4%)

Cash of $1.3M as of March 31, 2023, sufficient only on month-to-month basis; company requires additional financing.
Net loss of $3.5M for Q1 2023 improved $0.2M vs Q1 2022 net loss of $3.7M, aided by $1.0M deferred tax benefit.
G&A expenses rose 53.7% to $3.5M due to insurance, marketing, and PIPE failure payments.
VAR 200 investigator-initiated trial expected Q4 2023; IND submission for IC 100 anticipated Q2 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

ZyVersa Therapeutics, Inc. reported the first quarter of 2023 ending March 31, 2023 results: net income approximately $3.5 million.

Period: the first quarter of 2023 ending March 31, 2023
Net income: approximately $3.5 million
Result: reported results

Exact text from the filing

Net losses were approximately $3.5 million for the three months ended March 31, 2023

View on SEC.gov

Browse all earnings releases →

ZyVersa Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001493152-23-016793

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.